| Drug General Information |
| Drug ID |
D0WL5V
|
| Former ID |
DNC007125
|
| Drug Name |
LAROPIPRANT
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Phase 4 |
[1],
[2]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C21H19ClFNO4S
|
| InChI |
InChI=1S/C21H19ClFNO4S/c1-29(27,28)18-10-15(23)9-17-16-7-4-13(8-19(25)26)20(16)24(21(17)18)11-12-2-5-14(22)6-3-12/h2-3,5-6,9-10,13H,4,7-8,11H2,1H3,(H,25,26)/t13-/m1/s1
|
| InChIKey |
NXFFJDQHYLNEJK-CYBMUJFWSA-N
|
| CAS Number |
CAS 571170-77-9
|
| PubChem Compound ID |
|
| PubChem Substance ID |
14832522, 16319858, 24159188, 45289906, 79316133, 96025623, 103506442, 104083674, 125240979, 126671694, 126731356, 134339127, 134344330, 135195695, 136367874, 137185589, 139755590, 144116232, 152255074, 152258799, 152344287, 160647650, 162012049, 162205095, 163125572, 164023436, 172087022, 175266118, 178100382, 186014491, 204366771, 223398991, 223556714, 223674460, 225130865, 227246809, 247021101, 249816641, 251971100, 252451672
|
| Target and Pathway |
| Target(s) |
Thromboxane A2 receptor |
Target Info |
Inhibitor |
[3]
|
|---|
| Prostaglandin D2 receptor |
Target Info |
Inhibitor |
[3]
|
| Prostaglandin E2 receptor, EP1 subtype |
Target Info |
Inhibitor |
[3]
|
| Prostacyclin receptor |
Target Info |
Inhibitor |
[3]
|
| Putative G-protein coupled receptor 44 |
Target Info |
Inhibitor |
[3]
|
| Prostaglandin F2-alpha receptor |
Target Info |
Inhibitor |
[3]
|
| Prostaglandin E2receptor, EP2 subtype |
Target Info |
Inhibitor |
[3]
|
| Prostaglandin E2 receptor EP3 subtype |
Target Info |
Inhibitor |
[3]
|
|
KEGG Pathway
|
Calcium signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Platelet activationhsa04080:Neuroactive ligand-receptor interactionhsa04020:Calcium signaling pathway
|
|
Pathways in cancerhsa04080:Neuroactive ligand-receptor interaction
|
|
Vascular smooth muscle contraction
|
|
Platelet activationhsa04020:Calcium signaling pathway
|
|
Neuroactive ligand-receptor interactionhsa04024:cAMP signaling pathway
|
|
Inflammatory mediator regulation of TRP channels
|
|
Renin secretion
|
|
Pathways in cancerhsa04020:Calcium signaling pathway
|
|
cAMP signaling pathway
|
|
Regulation of lipolysis in adipocytes
|
|
Pathways in cancer
|
|
NetPath Pathway
|
IL2 Signaling Pathway
|
|
PANTHER Pathway
|
PI3 kinase pathway
|
|
Pathway Interaction Database
|
Thromboxane A2 receptor signalingtxa2pathway:Thromboxane A2 receptor signaling
|
|
PathWhiz Pathway
|
Intracellular Signalling Through PGD2 receptor and Prostaglandin D2PW000452:Intracellular Signalling Through Prostacyclin Receptor and Prostacyclin
|
|
Reactome
|
Prostanoid ligand receptors
|
|
G alpha (q) signalling events
|
|
G alpha (12/13) signalling events
|
|
Thromboxane signalling through TP receptorR-HSA-391908:Prostanoid ligand receptors
|
|
G alpha (s) signalling eventsR-HSA-391908:Prostanoid ligand receptors
|
|
G alpha (q) signalling eventsR-HSA-391908:Prostanoid ligand receptors
|
|
G alpha (i) signalling eventsR-HSA-391908:Prostanoid ligand receptors
|
|
G alpha (i) signalling events
|
|
WikiPathways
|
GPCRs, Class A Rhodopsin-like
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
Small Ligand GPCRs
|
|
Signal amplification
|
|
GPCR ligand binding
|
|
GPCR downstream signalingWP98:Prostaglandin Synthesis and Regulation
|
|
Endothelin Pathways
|
|
Platelet homeostasis
|
|
GPCR downstream signalingWP455:GPCRs, Class A Rhodopsin-like
|
|
GPCR downstream signaling
|
|
GPCRs, OtherWP98:Prostaglandin Synthesis and Regulation
|
|
Ovarian Infertility Genes
|
| References |
| REF 1 | ClinicalTrials.gov (NCT01126073) Niacin/Laropiprant and Endothelial Function. U.S. National Institutes of Health. |
|---|
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3356). |
|---|
| REF 3 | J Med Chem. 2007 Feb 22;50(4):794-806.Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524). |
|---|
